This study evaluated the effects of ATRA on annexin A2 and S100A10 expression, plasmin activation, and the ability of ATRA to inhibit serous ovarian cancer cell survival and invasion. This evidence concerns the gene ANXA2 and ovarian serous adenocarcinoma.